- Sitagliptin, sold
under the
brand name
Januvia among others, is an anti-diabetic
medication used to
treat type 2 diabetes. It is in the
dipeptidyl peptidase-4...
-
antibody used in
cancer immunotherapy that had $14.3
billion in 2020 revenue;
Januvia (sitagliptin), an anti-diabetic
medication used to
treat type 2 diabetes...
- time in 2010 for its work with
Merck & Co. on the
active ingredient in
Januvia. In 2017, the
company entered a
partnership with Tate & Lyle to provide...
-
class are:
Sitagliptin (FDA
approved 2006,
marketed by
Merck & Co. as
Januvia)
Vildagliptin (EU
approved 2007,
marketed in the EU by
Novartis as Galvus)...
- team at
Merck received the Prix
Galien USA
award for
their work on
Januvia™. The
Januvia™
project was the
first project at
Merck to be co-led
solely by women...
- This list
includes treatments for: Diabetes: Farxiga, Fiasp/NovoLog,
Januvia,
Jardiance Blood diseases: Eliquis, Xarelto,
Imbruvica Heart failure: Entresto...
- Food and Drug
Administration (FDA)
approved labeling changes stating that
Januvia (sitagliptin),
Janumet (sitagliptin and
metformin hydrochloride), and Janumet...
-
Boehringer Ingelheim Chronic obstructive pulmonary disease Apr-2002 2018-Jul 14
Januvia Sitagliptin 700,941 3.63%
Merck & Co., Inc.
Diabetes mellitus type 2 Dec-1996...
- 1021/jm050261p. PMID 16033281. "Bristol,
Takeda Drugs Offer Alternatives to
Januvia (Update2)". Bloomberg. 2008-06-07. "Safety
Alerts for
Human Medical Products...
-
product knowledge, and
process understanding. In 2006,
Merck & Co.'s
Januvia became the
first product approved based upon such an application. Implementation...
